High levels of intra-tumoral chemokines such as CCL5, CXCL9, CXCL10 enhance the recruitment of T-cells into the tumor[52] and preclinical studies in mice showed that infiltrating anti-tumor CD8+ T-cells are required for clinical response to anti-PD-1 treatment[53]. This evidence concerns the gene CXCL9 and neoplasm.